Wave Life Sciences WVE Proceeds from issuance of common stock relating to employee stock plans

Proceeds from issuance of common stock relating to employee stock plans at other companies

Beam TherapeuticsBEAM

——

Viridian Therapeutics, Inc.VRDN

——

Revenue$38.2M+317%

Operating income-$31.3M+37.2%

Net income-$26.1M+44.4%

EPS (diluted)-$0.13+55.2%

Cash & equivalents$544.6M+124%

Total debt$15.7M-33.4%

Total equity$511.7M+198%

Total assets$583.5M+102%

Operating cash flow-$59.6M+5.5%

CapEx$438.0K+165%

Free cash flow-$60.0M+5.1%

Market cap$1.14B+13.0%

Enterprise value$615.92M-22.3%

P/S15.1×-12.2×

Operating margin-75.7%-33.6pp

Net margin-66.5%-29.9pp

FCF margin-27.2%-12.6pp

Return on equity-53.7%—

Debt / equity0×-0.1×

Current ratio11.3×+8.3×

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockPlans.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Wave Life Sciences's proceeds from issuance of common stock relating to employee stock plans?: Wave Life Sciences (WVE) reported proceeds from issuance of common stock relating to employee stock plans of $593K in Q1 2026.
How has Wave Life Sciences's proceeds from issuance of common stock relating to employee stock plans changed year-over-year?: Wave Life Sciences's proceeds from issuance of common stock relating to employee stock plans increased by 34.2% year-over-year, from $442K to $593K.